Enrollment completed in Ph 2 Combi-TED Trial of Tedopi® in Combination with Nivolumab or Docetaxel in Patients with NSCLC
Federico Cappuzzo, M.D., Ph.D., Director Medical Oncology at Cancer Institute Regina Elena, Roma, Italy, and Chief Investigator of the study, comments: “We are very pleased to announce the completion of enrollment in Combi-TED, an exploratory Phase 2 evaluating a new treatment strategy with the combination of therapeutic cancer vaccine Tedopi® which, by activating T lymphocytes, might efficiently optimize a checkpoint inhibitor or chemotherapy treatment. We are now looking forward to the results of this study, expected in 2026, as they will contribute to guiding the next steps in the development of new therapies for NSCLC patients progressing after at least three months (four cycles) of first-line chemo-immunotherapy, and eligible for treatment with docetaxel, a population who needs new treatment options.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.